跳至主要内容
临床试验/NCT02495935
NCT02495935Unknown不适用

Feasibility and Efficacy of Transcorneal Electrical Stimulation (TES) for the Treatment of Amblyopia

Wills Eye2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2015年7月1日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
40
试验地点
2
主要终点
Mean change in Best Corrected Visual Acuity (ETDRS letters)

研究概览

简要总结

This is a prospective, randomized, parallel group sham-controlled blinded clinical trial to assess the feasibility and efficacy of transcorneal electrical stimulation (TES) in the improvement of visual function outcomes in adults with amblyopia. The trial will assess the treatment effect of TES to Sham TES in the amblyopic eye of affected patients.

详细描述

Amblyopia is defined as a decrease in visual acuity in one eye, despite the correction of any refractive error with glasses and in the absence of any ophthalmoscopically visible lesion of the retina, especially of the macular region. Amblyopia is associated with histologic and electrophysiologic abnormalities in the visual pathways.

Transcorneal electrical stimulation (TES), through neural stimulation, works by non-invasively stimulating the retina via passage of electrical current directly to the retina, bypassing the usual light activation pathway, resulting in the activation of the same areas of the brain as would be activated with a light stimulus alone. Electrical stimulation with TES has shown potential in recent reports as an efficacious treatment modality to improve visual function.

The success of electrical stimulation in neurodegenerative disorders provides a reasonable rationale and significant precedent to investigate its potential for use in disorders of the visual processing system, which functions via an integration of biochemical and electrical interactions transmitted from the retina.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years
  • Diagnosis of amblyopia made by the principal investigators.
  • Best corrected visual acuity in the amblyopic eye equal to or worse than 20/70
  • Willing and able to give informed consent and to participate for the full duration of the study.
  • Strabismus less than 10 prism diopters.

排除标准

  • Any other significant ophthalmologic disorder or condition with relevant effect upon visual function as evaluated by principal investigator. (eg. Retinal degeneration, proliferative diabetic retinopathy, age related macular degeneration, optic nerve abnormality)
  • Women who are pregnant or women with childbearing potential who are unwilling to use medically acceptable means of birth control for study duration.
  • Presence of a pacemaker, any metal artifacts in head and trunk, any history of epileptic seizure or severe psychiatric disease (schizophrenia, etc.)
  • Inability to detect phosphenes above 0.5mA at time of threshold detection.

结局指标

主要结局

Mean change in Best Corrected Visual Acuity (ETDRS letters)

时间窗: 16 weeks

Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) to Week 16 (4 weeks post last treatment).

次要结局

未报告次要终点

研究者

发起方
Wills Eye
申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. Leonard B. Nelson

MD

Wills Eye

研究点 (2)

Loading locations...

相似试验